Vontobel Financial Products GmbH Stock

Certificat

DE000VM7GUW2

Real-time Boerse Frankfurt Warrants 04:20:21 2024-06-27 EDT
45.5 EUR -2.38% Intraday chart for Vontobel Financial Products GmbH
Current month-0.87%
1 month-3.94%
Date Price Change
24-06-27 45.5 -2.38%
24-06-26 46.61 +0.32%
24-06-25 46.46 +2.99%
24-06-24 45.11 +1.42%
24-06-21 44.48 -1.72%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 04:20 am

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer Vontobel Vontobel
WKN VM7GUW
ISINDE000VM7GUW2
Date issued 2024-01-03
Strike 24
Maturity 2024-12-20 (177 Days)
Parity 0.02 : 1
Emission price 100
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 92.5
Lowest since issue 40.68
Spread 1
Spread %0.22%

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.775 EUR
Average target price
20.79 EUR
Spread / Average Target
+136.92%
Consensus